Date: Nov 30, 2011 Source: (
click here to go to the source)
In light of progress made with the initial contract for $100,000 awarded in December, 2009, VLP has received two more rounds of funding: $250,000 in March, 2011, and $500,000 in November, 2011. This funding will be used to further improve and optimize the vaccine candidate developed under the initial agreement. To date there is no prophylactic vaccine for the targeted pathogen which is the leading worldwide agent of serious pediatric respiratory tract disease.
